Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
128M
-
Number of holders
-
261
-
Total 13F shares, excl. options
-
115M
-
Shares change
-
+3.27M
-
Total reported value, excl. options
-
$4.43B
-
Value change
-
+$34.6M
-
Put/Call ratio
-
0.14
-
Number of buys
-
149
-
Number of sells
-
-130
-
Price
-
$38.36
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2024
357 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q2 2024.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 261 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 115M shares
of 128M outstanding shares and own 90.39% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (16.4M shares), EcoR1 Capital, LLC (11.6M shares), Avoro Capital Advisors LLC (11.1M shares), VANGUARD GROUP INC (9.81M shares), BlackRock Inc. (5.8M shares), STATE STREET CORP (4.15M shares), T. Rowe Price Investment Management, Inc. (4.05M shares), JENNISON ASSOCIATES LLC (3.59M shares), FMR LLC (3.3M shares), and JPMORGAN CHASE & CO (3.18M shares).
This table shows the top 261 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.